Tzung-Dau Wang Selected Research

Essential Hypertension

2/2022	Preprocedural features of patients under antihypertensive drugs may help identify responders to renal denervation: a hypothesis-generating study.
1/2021	Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan.
1/2013	Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tzung-Dau Wang Research Topics

Disease

43	Hypertension (High Blood Pressure) 03/2024 - 01/2013
11	Heart Failure 03/2024 - 02/2010
11	Heart Arrest (Cardiac Arrest) 01/2019 - 08/2009
7	Stroke (Strokes) 07/2023 - 01/2015
6	Out-of-Hospital Cardiac Arrest 02/2017 - 02/2004
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 06/2013
5	Shock 01/2023 - 12/2011
5	Inflammation (Inflammations) 07/2017 - 01/2003
5	Asphyxia (Suffocation) 01/2016 - 11/2008
5	Hypothermia 11/2015 - 08/2009
4	Myocardial Infarction 07/2023 - 09/2006
4	Chronic Renal Insufficiency 01/2022 - 01/2015
4	Coronary Disease (Coronary Heart Disease) 01/2022 - 10/2003
4	Dyslipidemias (Dyslipidemia) 01/2021 - 06/2004
4	Body Weight (Weight, Body) 01/2020 - 10/2010
3	Obesity 03/2024 - 11/2019
3	Hyperaldosteronism (Conn Syndrome) 03/2024 - 12/2017
3	Diabetes Mellitus 10/2023 - 08/2007
3	Reperfusion Injury 01/2023 - 01/2003
3	Insulin Resistance 01/2023 - 11/2007
3	Essential Hypertension 02/2022 - 01/2013
3	Atherosclerosis 01/2022 - 07/2017
3	Masked Hypertension 01/2021 - 01/2020
3	Ventricular Fibrillation 01/2017 - 12/2011
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2009 - 02/2004
2	Type 2 Diabetes Mellitus (MODY) 01/2024 - 12/2013
2	Overweight 10/2023 - 04/2019
2	Ischemic Stroke 02/2023 - 01/2022
2	Ischemia 01/2023 - 04/2002
2	Pathologic Constriction (Stenosis) 01/2021 - 11/2010
2	COVID-19 05/2020 - 01/2020
2	Hyperuricemia 01/2020 - 11/2019
2	Acute Coronary Syndrome 01/2019 - 08/2007
2	Proteinuria 05/2017 - 01/2015
2	Coronary Artery Disease (Coronary Atherosclerosis) 11/2010 - 09/2006
2	Spinal Cord Injuries (Spinal Cord Injury) 10/2009 - 10/2005
1	Liver Diseases (Liver Disease) 01/2024
1	Restrictive Cardiomyopathy 07/2023
1	Cardiomyopathies (Cardiomyopathy) 07/2023
1	Amyloidosis 07/2023
1	Prediabetic State (Prediabetes) 01/2023
1	Mesenteric Ischemia 01/2023

Drug/Important Bio-Agent (IBA)

19	Antihypertensive Agents (Antihypertensives)IBA 01/2024 - 05/2014
8	SaltsIBA 03/2024 - 10/2010
8	4- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamineIBA 01/2023 - 01/2020
7	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 10/2006
6	CholesterolIBA 01/2022 - 01/2003
6	C-Reactive ProteinIBA 11/2010 - 10/2003
4	Angiotensin Receptor AntagonistsIBA 05/2022 - 01/2013
4	SodiumIBA 01/2022 - 01/2015
4	LipidsIBA 01/2013 - 10/2003
3	Biomarkers (Surrogate Marker)IBA 10/2023 - 01/2016
3	CalciumIBA 01/2021 - 11/2010
3	CreatinineIBA 01/2020 - 11/2007
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 10/2003
3	Insulin (Novolin)FDA Link 12/2013 - 10/2006
3	CD40 Ligand (CD40L)IBA 11/2007 - 10/2003
2	NAD (NADH)IBA 01/2023 - 01/2023
2	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 05/2022 - 01/2020
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 05/2022 - 01/2013
2	Uric Acid (Urate)IBA 01/2022 - 01/2020
2	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2021 - 01/2017
2	LDL CholesterolIBA 01/2021 - 10/2009
2	PotassiumIBA 01/2021 - 01/2017
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020 - 11/2010
2	omega-Chloroacetophenone (Mace)IBA 01/2019 - 12/2017
2	Lidocaine (Xylocaine)FDA LinkGeneric 02/2017 - 01/2017
2	Amiodarone (Amiodarona)FDA LinkGeneric 02/2017 - 01/2017
2	Valsartan (Vals)FDA Link 01/2017 - 01/2013
2	Fatty Acid-Binding ProteinsIBA 08/2014 - 08/2009
2	Ascorbic Acid (Vitamin C)FDA LinkGeneric 12/2011 - 09/2009
2	Serum AlbuminIBA 10/2009 - 11/2007
2	ResistinIBA 02/2009 - 10/2006
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 11/2007 - 10/2006
2	Interleukin-6 (Interleukin 6)IBA 11/2007 - 10/2006
2	Endothelin-1 (Endothelin 1)IBA 11/2007 - 10/2006
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 11/2007 - 10/2006
2	AdiponectinIBA 10/2006 - 10/2005
2	Rosiglitazone (Avandia)FDA Link 10/2006 - 02/2004
2	Interleukin-1beta (Interleukin 1 beta)IBA 10/2003 - 01/2003
2	Caspase 3 (Caspase-3)IBA 01/2003 - 04/2002
1	Natriuretic PeptidesIBA 03/2024
1	A-factor (Streptomyces)IBA 01/2024
1	Amyloid (Amyloid Fibrils)IBA 07/2023
1	Prealbumin (Transthyretin)IBA 07/2023
1	PorphyrinsIBA 01/2023
1	Riboflavin (Vitamin B2)FDA LinkGeneric 01/2023
1	Blood Glucose (Blood Sugar)IBA 01/2023
1	Indicators and Reagents (Reagents)IBA 01/2023
1	FlavinsIBA 01/2023

Therapy/Procedure

19	Therapeutics 07/2023 - 10/2003
9	Denervation 12/2022 - 05/2019
6	Cardiopulmonary Resuscitation (CPR) 01/2017 - 02/2004
6	Resuscitation 01/2017 - 02/2004
5	Induced Hypothermia 11/2017 - 08/2009
4	Induced Heart Arrest (Cardioplegia) 01/2016 - 11/2008
2	Secondary Prevention 01/2022 - 09/2007
2	Percutaneous Coronary Intervention 11/2017 - 08/2007
1	Drug Therapy (Chemotherapy) 10/2023
1	Thrombectomy 02/2023